| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | 1,321.5 | -40.7 |
| Net income | 1,166.2 | -40.7 |
| EPS (diluted, $ a share) | $9.65 | $-0.39 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: EWTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Edgewise Therapeutics, Inc.: key numbers
- Share price
- $42.04Close, Nov 17
- Market cap
- $4.6B
- Shares outstanding
- 109.48MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Edgewise Therapeutics, Inc.
All →Edgewise Therapeutics CFO Michael Nofi Sells $202K of Stock
Michael Nofi, CFO, sold 4,442 shares of Edgewise Therapeutics, Inc. at $45.43 a share, worth $202K in total on Nov 10, 2026. Shares held after the trade: 6,495 (-40.6%).
- Value
- $202K
- Shares
- 4,442
- Price
- $45.43
- Role
- CFO
- Holding change
- -40.6%
- Trade date
- Nov 10, 2026
Edgewise Therapeutics Financial Results
Edgewise Therapeutics reported Q3 2026 financial results, highlighting a $1.348 billion gain from the sale of sevasemten to Servier. The company ended the quarter with $1.74B in cash and is on track to initiate a Phase 3 trial for EDG-7500 in HCM by year-end 2026.
“Our third quarter reflects continued execution across both cardiovascular programs. In HCM, positive CIRRUS-HCM Part D results and our JCI Insight publication reinforce the differentiated profile of EDG-7500, and we expect to initiate our Phase 3 trial by year-end 2026.”
Kevin Koch, Ph.D., President and Chief Executive Officer